Baseline characteristics
| Characteristic . | ITT population (N = 682) . |
|---|---|
| Median age, y (range) | 66 (37-88) |
| >65, n (%) | 369 (54.1) |
| >70, n (%) | 213 (31.2) |
| >75, n (%) | 87 (12.8) |
| Sex, n (%) | |
| Male | 381 (55.9) |
| Female | 301 (44.1) |
| Median time since initial diagnosis, y (range) | 5.3 (0.6-28.2) |
| ECOG performance status, n (%) | |
| 0-1 | 614 (90.0) |
| 2-3 | 68 (10.0) |
| ISS stage at study entry, n (%) | |
| I-II | 414 (60.7) |
| III | 236 (34.6) |
| Missing | 32 (4.7) |
| CrCl < 60 mL/min, n (%) | 237 (34.8) |
| Median prior regimens, n (range) | 5 (2-18) |
| >2 previous regimens, n (%) | 637 (93.4) |
| Prior dexamethasone, n (%) | 666 (97.7) |
| Prior lenalidomide, n (%) | 682 (100.0) |
| Prior bortezomib, n (%) | 682 (100.0) |
| Prior thalidomide, n (%) | 372 (54.5) |
| Prior carfilzomib, n (%) | 24 (3.5) |
| Prior stem cell transplant, n (%) | 451 (66.1) |
| Lenalidomide refractory, n (%) | 654 (95.9) |
| Bortezomib refractory, n (%) | 571 (83.7) |
| Lenalidomide and bortezomib refractory, n (%) | 547 (80.2) |
| Characteristic . | ITT population (N = 682) . |
|---|---|
| Median age, y (range) | 66 (37-88) |
| >65, n (%) | 369 (54.1) |
| >70, n (%) | 213 (31.2) |
| >75, n (%) | 87 (12.8) |
| Sex, n (%) | |
| Male | 381 (55.9) |
| Female | 301 (44.1) |
| Median time since initial diagnosis, y (range) | 5.3 (0.6-28.2) |
| ECOG performance status, n (%) | |
| 0-1 | 614 (90.0) |
| 2-3 | 68 (10.0) |
| ISS stage at study entry, n (%) | |
| I-II | 414 (60.7) |
| III | 236 (34.6) |
| Missing | 32 (4.7) |
| CrCl < 60 mL/min, n (%) | 237 (34.8) |
| Median prior regimens, n (range) | 5 (2-18) |
| >2 previous regimens, n (%) | 637 (93.4) |
| Prior dexamethasone, n (%) | 666 (97.7) |
| Prior lenalidomide, n (%) | 682 (100.0) |
| Prior bortezomib, n (%) | 682 (100.0) |
| Prior thalidomide, n (%) | 372 (54.5) |
| Prior carfilzomib, n (%) | 24 (3.5) |
| Prior stem cell transplant, n (%) | 451 (66.1) |
| Lenalidomide refractory, n (%) | 654 (95.9) |
| Bortezomib refractory, n (%) | 571 (83.7) |
| Lenalidomide and bortezomib refractory, n (%) | 547 (80.2) |
ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System.